Abazari, A. Process development considerations for cryopreservation of cellular therapies. Cell & Gene Therapy Insights. 2019; 5(9), 1151–1167. doi: 10.18609/cgti.2019.122
Read MoreBahsoun, S., Coopman, K., Akam, E. C.. The impact of cryopreservation on bone marrow-derived mesenchymal stem cells: a systematic review. Journal Of Translational Medicine. 2019; 17(1). doi: 10.1186/s12967-019-02136-7
Read MoreThe Impact of feeding regimen and cell cycle on post-thaw recovery in a human T-cell model
Read MoreMeneghel, J., Kilbride, P., Morris, J. G. and Fonseca, F. Physical events occurring during the cryopreservation of immortalized human T cells. PLOS ONE. 2019; 14(5), e0217304. doi: 10.1371/journal.pone.0217304
Read MoreMcCreedy, B. J., Senyukov, V. V., Nguyen, K. T. Off the shelf T cell therapies for hematologic malignancies. Best Practice & Research Clinical Haematology 2018; 31(2), 166-175. doi: 10.1016/j.beha.2018.03.001.
Read MoreMontanari, E., Pimenta, J., Szabó, L., Noverraz, F., Passemard, S., Meier, R. P. H., Meyer, J., Sidibe, J., Thomas, A., Schuurman, H., Gerber-Lemaire, S., Gonelle-Gispert, C. and Buhler, L. H. Beneficial Effects of Human Mesenchymal Stromal Cells on Porcine Hepatocyte Viability and Albumin Secretion. Journal of Immunology Research 2018, Article ID 1078547: 1-13. doi:10.1155/2018/1078547
Read MoreAbazari A, Hawkins BJ, Clarke DM, Mathew AJ. Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study. Cell Gene Therapy Insights 2017; 3(10), 853-871. DOI: 10.18609/cgti.2017.082
Read MoreAbazari A, Hawkins BJ, Clarke DM, Mathew AJ. Biopreservation Best Practices: A Cornerstone in the Supply Chain of Cell-based Therapies – MSC Model Case Study. Cell Gene Therapy Insights 2017; 3(10), 853-871. DOI: 10.18609/cgti.2017.082
Read MoreBaust, Campbell, Harbell. Best practices for cryopreserving, thawing, recovering, and assessing cells. In Vitro Cell.Dev.Biol.—Animal. DOI 10.1007/s11626-017-0201-y
Read MoreKevin O’Donnell. Cell and Gene Therapies in Transit: Caution – Hazards Ahead: The Cell & Gene Therapy Manufacturing Pathway – Part 2. Cell and Gene Therapy Insights. 2016; 2(2), 271-276. doi: 10.18609/cgti.2016.031
Read More